63. J Allergy Clin Immunol Glob. 2024 Sep 6;3(4):100339. doi: 
10.1016/j.jacig.2024.100339. eCollection 2024 Nov.

Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 
vaccine.

Esmailian A(1), Barnes SL(1)(2)(3), Pumar M(3).

Author information:
(1)Faculty of Medicine, Monash University, Melbourne, Australia.
(2)Monash Lung Sleep Allergy and Immunology, Clayton, Australia.
(3)Monash Health, Clayton, Australia.

We present a case of secondary T-cell deficiency particularly affecting CD4 T 
cells, along with the emergence of chronic spontaneous urticaria in a patient 
following COVID-19 vaccination. The condition was partially managed with 
omalizumab after initial first-line therapy proved ineffective.

Â© 2024 The Authors.

DOI: 10.1016/j.jacig.2024.100339
PMCID: PMC11459643
PMID: 39380982

Conflict of interest statement: Disclosure of potential conflict of interest: 
The authors declare that they have no relevant conflicts of interest.